ACTUATE THERAPEUTICS

Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting

07 May 2025 08:00:01 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer

06 May 2025 08:00:01 By Nasdaq GlobeNewswire

Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025

30 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

23 Apr 2025 10:24:10 By Nasdaq GlobeNewswire

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

17 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer

25 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

06 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

07 Jan 2025 08:00:01 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

17 Dec 2024 08:28:17 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

17 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Actuate Therapeutics to be Added to Russell 2000® Index

26 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

12 Nov 2024 08:00:03 By Nasdaq GlobeNewswire

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

29 Oct 2024 18:39:24 By Nasdaq GlobeNewswire

Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor

23 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research

16 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas

11 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

09 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05 Sep 2024 09:10:56 By Nasdaq GlobeNewswire

Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024

20 Aug 2024 09:00:00 By Nasdaq GlobeNewswire